12 news items
Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5
URGN
14 Jun 24
Ladenburg Thalmann analyst Matthew Kaplan maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $48 to $53.5.
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
ADBE
ARM
ECX
14 Jun 24
the stock from Neutral to Buy and raised its price target from $70 to $80
Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40
URGN
14 Jun 24
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and raises the price target from $32 to $40.
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
ADBE
APA
BAC
14 Jun 24
the price target for UroGen Pharma Ltd. (NASDAQ:URGN) from $54
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $60
URGN
14 Jun 24
HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $54 to $60.
v994eitnroph35tyud8qy8g 3t7ejtk9
URGN
13 Jun 24
-NMIBC. The Phase 3 ENVISION trial completed target enrollment with approximately 240 patients across 56 sites. Study participants received six once
x9hlggz4nfruwlyd9w3qj03mvbprnp3ltp
URGN
14 May 24
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $34 to $32.
jqmg02 72
URGN
14 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price target.
9bisop3ev67n12z63o70zgefe2vr87fn5wlc9m1b0nwp7jyvdr71
URGN
6 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price target.
61jucakts2x1 a4epyk6m9cs2skzapcyp03ma
URGN
4 May 24
solution as primary chemoablative therapy in patients with LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with approximately 240
1br3uyc4lqf8yugfmqtekwe2q
URGN
18 Apr 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price target.
6cv39j4ho5lo6chjqar0a4a
URGN
4 Apr 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price target.
- Prev
- 1
- Next